Bio-Techne (TECH) Financial Analysis & Valuation | Quarter Chart
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protei... more
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life scien... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $11.39B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Kim Kelderman |
| IPO Date | 1989-02-09 | CAGR | 13.17% |
| Employees | 3,000 | Website | www.bio-techne.com |
| Div. Yield | 0.44% | Payout Ratio | 7% |
| Buy Back Yield | 0.37% | Total Yield | 0.81% |
TECH chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $11.12B | P/E | 37.43 | Forward P/E | 31.41 | PEG | — |
| P/S | 11.04 | P/B | 6.35 | P/CF | 139.87 | P/FCF | 154.11 |
| Sales | $1.22B | Sales 1Y | -0.38% | Sales 3Y | 6.89% | Sales 5Y | 30.5% |
| EPS | $1.94 | EPS 1Y | 152.17% | EPS 3Y | -34.09% | EPS 5Y | 33.13% |
| Sales QoQ | 3.14% | EPS QoQ | 12.5% | Sales QoQ Avg | 0.51% | EPS QoQ Avg | -68.09% |
| Gross Margin | 65.77% | Operating Margin | 20.73% | Profit Margin | 14.97% | ROCE | 10.4% |
| ROA | 7% | ROE | 9% | Altman Z Score | 15.33 | Piotroski Score | 7 |
| Current Ratio | 4.55 | Quick Ratio | 3.35 | Cash Ratio | 1.62 | Op. CF Ratio | 0.58 |
| Debt/Equity | 0.13 | Debt/Assets | 0.11 | Lt Debt/Equity | 0.13 | Lt Debt/Cap. | 0.09 |
| Intrst Cov. | 46.6 | Inventory Turnover | 2.13 | Asset Turnover | 0.47 | Receivables Turnover | 5.61 |
| Enterprise Value | $11.12B | P/E Ratio | 37.43 |
| Forward P/E | 31.41 | PEG Ratio | — |
| P/S Ratio | 11.04 | P/B Ratio | 6.35 |
| P/CF Ratio | 139.87 | P/FCF Ratio | 154.11 |
| EPS | $1.94 | EPS Growth 1Y | 152.17% |
| EPS Growth 3Y | -34.09% | EPS Growth 5Y | 33.13% |
| Revenue Growth 1Y | -0.38% | Gross Margin | 65.77% |
| Operating Margin | 20.73% | Profit Margin | 14.97% |
| ROE | 9% | ROA | 7% |
| ROCE | 10.4% | Current Ratio | 4.55 |
| Quick Ratio | 3.35 | Cash Ratio | 1.62 |
| Debt/Equity | 0.13 | Interest Coverage | 46.6 |
| Altman Z Score | 15.33 | Piotroski Score | 7 |
Bio-Techne (TECH) valuation & financials
Bio-Techne (TECH) has a market capitalization of $11.39B and trades at a price-to-earnings ratio of 37.4. It operates in the Healthcare sector (Biotechnology).
Bio-Techne's revenue grew -0.4% over the last year.
Bio-Techne's next earnings report is scheduled for November 4, 2026 (provider scheduled date); analysts estimate EPS of $0.44. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)